Skip To Main Content
Simon Call on Muck Rack

Simon Call

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Simon Call’s profile

Articles by Simon Call

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis

|
By Philipp Berning, Markus Maulhardt, Snjezana Janjetovic, Anna Ossami Saidy, Christian Schultze-Florey, Simon Call, Friedrich Stölzel, Annamaria Brioli, Michael Daskalakis, Rebecca I. Wurm-Kuczera, Matthias Stelljes, Cyrus Khandanpour, Ulrike Bacher, Amelie Boquoi, Florian H. Heidel, Hans Reinhardt, Gerald G. Wulf, Natalie Schub, Bastian von Tresckow, Georg Lenz, Thomas Pabst, Evgenii Shumilov, Hristo Boyadzhiev, Anca-Maria Albici, Juliane Knust, Justin Hasenkamp, Alexander Pohlmann
| Nature Verified
Dear Editor, The introduction of chimeric antigen receptor T-cell (CAR-T) therapies has significantly transformed the treatment landscape for patients with relapsed/refractory (r/r) multiple myeloma (MM). BCMA-directed CAR-T cell therapies, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), have revolutionized the field by demonstrating remarkable efficacy in pivotal clinical trials [1, 2].
Open in Who Shared Issue with article?
Show More